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A bstr a ct 
 
The Office of the Surgeon General recently produced its first Report on the consequences 
of alcohol and drug abuse on health, making several very laudable policy 
recommendations.  The Report also emphasizes the importance of adequate funding for 
biomedical research, which is good news for both researchers and patients.  However, the 
Report is marred by a biased viewpoint on the psychology and neurobiology of drug 
addiction.  We highlight here four controversial issues that were depicted as facts in the 
Report, thereby potentially misleading non-expert readers about the current state-of-the-art 
understanding of the psychology and neurobiology of drug addiction.  It will be important 
to recognize a fuller range of scientific viewpoints in addiction neuroscience to avoid 
amplifying this bias in the coming years. 
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The first ever Surgeon General’s Report on the consequences of alcohol and drug abuse 
on health was published on November 17th, 2016 (https://addiction.surgeongeneral.gov/).  
The report draws attention to a problem of epidemic proportions, as indicated by the fact 
that more than 6% of the United States population has a substance use disorder and an 
estimated 135,000 people die prematurely every year as a consequence of drug overdose 
and alcohol abuse.  As the Surgeon General is the leading spokesperson on matters of 
public health in the United States, the content of this Report deserves to be analysed in 
detail. 
 
M uch to commend in the Sur geon Gener a l’s  Repor t  
To begin with, the Surgeon General’s Report should be commended for comprehensively 
examining the substance use disorder problem, and making several important 
recommendations aimed at boosting and expanding prevention, treatment, and recovery 
services in order to reduce the public health consequences associated with alcohol and 
drug use.  We particularly applaud the Report’s effort to draw attention to the unfortunate 
stigma of addictive disorders and the special needs of different patient populations, and its 
call for families, educators, state and federal authorities to contribute to this effort. 
 
In addition to making policy recommendations, the Report also emphasizes the importance 
of adequate funding for biomedical research, by recognizing that such research is vital to 
obtaining findings that can improve clinical and public health approaches to substance 
misuse and related disorders.  This is good news for both researchers in the field of drug 
addiction, and for patients and their families.  A large body of addiction neuroscience 
research during the last three decades has made major inroads into the neurobiological 
underpinnings of substance use disorders.  But much more remains to be done, and 
expanding this area of research is essential for the development of novel and more effective 
preventive and therapeutic approaches directed at curbing substance use disorders. 
 
A  bia sed scientific view point 
However, the Report falls short in meeting its stated aim of “bringing together the best 
available science” regarding the psychology and neurobiology of drug addiction.  The very 
selective choice of empirical and theoretical papers included in Chapter 2 of the Report 
has produced a limited – perhaps even biased – viewpoint, which primarily reflects a single 
addiction model, namely that known as the reward deficiency or allostasis model.  While 
that has been a major model, it is also highly controversial, and the Report neglects 
alternatives that might turn out be more successful.  Given that the Report provides 
guidelines for future neurobiological research and funding, there is a risk that this bias will 
be amplified in the coming years.   
 
Below we provide a critique and commentary on four key controversial issues that were 
depicted as facts in the Report, thereby potentially misleading readers about the current 
state-of-the-art understanding of the psychology and neurobiology of drug addiction. 
 
This article is protected by copyright. All rights reserved.
4  
A ddictive dr ugs  a r e not the sa me 
The first issue is that the Report seemingly endorses the notion that the reinforcing effects 
of all addictive drugs are essentially the same, and due to the activation of dopaminergic 
systems of the brain, although the available evidence does not support this claim.  For 
example, it has been known since the early 1980s that heroin’s direct reinforcing effects do 
not require dopamine, although dopamine may be important for opioid cue-triggered 
craving and relapse  (Badiani et al, 2011; Nutt et al, 2015).   
 
The Report also suggests that all addictive drugs produce similar neuroadaptations in the 
brains of addicts, but different drugs also produce unique neuroadaptations that are 
important to consider (Badiani et al, 2011).  In fact, the exact role of dopamine in 
mediating the rewarding effects of the many different drugs of abuse and related 
neuroadaptations remains an active area of investigation, and differences continue to 
emerge (e.g., Becker et al, 2016). 
 
Dopa mine a nd plea sur e:  a n out-of-da te notion 
A second issue concerns the nature of drug reward.  The Report appears to equate the 
reinforcing effects of drugs (which refer to changes in the frequency of a behavioral 
response, as acknowledged on page 2-8) to their pleasurable/hedonic effects.  Although it is 
often thought that positive reinforcement is associated with feelings of pleasure, many 
researchers believe that chief brain mechanisms underlying drug abuse are separable from 
those responsible for the pleasant states associated to drug use, as well as those responsible 
for the unpleasant states of withdrawal when drug use is halted (Berridge and Kringelbach, 
2014; Robinson and Berridge 2008; Shaham et al, 1996). 
 
The Report also suggests that brain dopamine release is the chief cause of drug-induced 
euphoria.  This is a throwback to the out-of-date notion that dopamine is the brain’s 
‘pleasure transmitter’, a notion that still holds sway in the popular media but it has been 
largely debunked in the scientific literature (Berridge and Kringelbach, 2014).  For 
example, on page 2-19, it is stated: “Opioids attach to opioid receptors in the brain, which 
leads to a release of dopamine in the nucleus accumbens, causing euphoria (the high)”, 
even though it has repeatedly been shown that the ‘high’ produced by heroin or by heroin-
paired cues is not associated with alterations in dopaminergic transmission in the dorsal or 
ventral striatum (Nutt et al, 2015). 
 
Str ess ,  CRF,  a nd a ddiction:  a  ta r get fa ilur e 
The Report focuses much attention on the importance of stress in the development of drug 
addiction and great prominence is given to the role of the stress neurohormone, 
corticotropin releasing factor (CRF), as the brain mechanism of drug withdrawal distress 
and cause of excessive drug use and relapse.  There is little doubt that exposure to acute 
or chronic stress plays a significant role in drug addiction and relapse (Badiani et al, 2011; 
Shaham et al, 1996).  Furthermore, studies using animal models have demonstrated a 
critical role of CRF in stress-induced drug seeking (Badiani et al, 2011; Shaham et al, 1996), 
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leading to the hypothesis that CRF plays a key role for in drug and alcohol dependence 
(Heilig and Koob, 2007).  Yet, to date all attempts at developing CRF-based therapies for 
human addiction (or other psychiatric disorders) have been unsuccessful (Schwandt et al, 
2016; Shaham and de Wit 2016) and major pharmaceutical companies have uniformly 
abandoned their development programs aimed at this target.  The fact that no reference to 
the known failures in targeting this mechanism was made in the Report provides the 
readers with an unbalanced picture of the state of research in this area. 
 
A ddiction in theor y 
Finally, not only does the Report focus on shared neurobiological underpinnings of short- 
and long-term drug effects but it also endorses a particular unitary theoretical model of 
addiction championed by one of the Science Editors (the three-stage hedonic allostasis or 
reward deficit model described on pages 2-6 to 2-18).  A reader of the Report not familiar 
with the relevant literature may be surprised to learn that only some researchers subscribe 
to the hedonic allostasis theory.  Many others do not concur with this view and support 
different theoretical accounts of addiction built around processes such as aberrant learning, 
impaired executive (inhibitory) control over behavior and incentive-sensitization to drug use 
and drug cues (e.g., Robinson and Berridge, 2008; Everitt and Robbins, 2016). These 
alternative views are major live topics in addiction neuroscience today, but receive short-
shrift in the Report. 
 
Other researchers question altogether the explanatory value of unified addiction theories 
cutting across drug classes, because they do not easily reconcile with the well-known 
differences among opiate, psychostimulant, and alcohol abuse in terms of epidemiology, 
personality traits, neurobiological mechanisms, drug-induced brain neuroadaptations, and 
therapeutic approaches (Badiani et al, 2011; Nutt et al, 2015). 
 
Conclus ions 
We recognize that a scientific mission statement requires a certain degree of simplification 
to be effective.  Still, the scientific perspective of the Surgeon General’s Report is too 
narrow and too limited in depth to achieve its presumed aims.   
 
In the age of personalized medicine, a ‘one-size-fits-all’ approach in clinical addiction 
medicine, requires reconsideration.  Propagating an out-of-date view that all addictive 
drugs are the same in producing pleasure by activating the “brain reward systems” is 
counterproductive in that context (even if there might be some convergence or overlap in 
brain mechanisms of addiction).  Furthermore, no attempt at simplification should ignore 
the fundamental role played by genetic, sex-related, and environmental factors when it 
comes to the ability of commonly used drugs to activate dopaminergic circuitry (Badiani et 
al, 2011).   
 
Also counterproductive is the attempt at enforcing the notion that there is a substantial 
agreement in the field concerning the theoretical framework informing addiction research.  
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The truth is that there are competing theories and only time will tell which of them (if any) 
has been more useful in leading to a better understanding of the psychology and 
neurobiology of drug addiction and to more effective therapies. 
 
It will be important for such points to be recognized to ensure that the Report's 
authoritative nature does not bias the direction of future neurobiological research. 
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